What is the recommended dosing regimen for oxcarbazepine (Trileptal) in adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Trileptal (Oxcarbazepine) Dosing

For adults with partial-onset seizures, initiate Trileptal at 600 mg/day divided twice daily, with weekly increases of 600 mg/day as needed up to a maximum of 2400 mg/day; for children aged 4-16 years, start at 8-10 mg/kg/day divided twice daily, titrating over 2 weeks to weight-based maintenance doses of 900-1800 mg/day. 1

Adult Dosing

Adjunctive Therapy

  • Starting dose: 600 mg/day (300 mg twice daily) 1
  • Titration: Increase by maximum 600 mg/day at weekly intervals 1
  • Target maintenance: 1200 mg/day 1
  • Maximum dose: 2400 mg/day (though most patients cannot tolerate this due to CNS effects) 1

Conversion to Monotherapy

  • Initial dose: 600 mg/day (twice daily) while simultaneously reducing concomitant AEDs 1
  • Titration: Increase by 600 mg/day weekly to reach maximum 2400 mg/day over 2-4 weeks 1
  • Concomitant AED withdrawal: Complete over 3-6 weeks 1
  • Effective maintenance: 1200 mg/day has proven effective in monotherapy trials 1

Initiation of Monotherapy (Treatment-Naive Patients)

  • Starting dose: 600 mg/day (twice daily) 1
  • Titration: Increase by 300 mg/day every third day 1
  • Target dose: 1200 mg/day 1

Pediatric Dosing

Children Aged 4-16 Years (Adjunctive Therapy)

  • Starting dose: 8-10 mg/kg/day (not exceeding 600 mg/day), divided twice daily 1
  • Titration period: Achieve target over 2 weeks 1
  • Weight-based maintenance doses: 1
    • 20-29 kg: 900 mg/day
    • 29.1-39 kg: 1200 mg/day
    • 39 kg: 1800 mg/day

  • Clinical trial data: Median dose was 31 mg/kg/day (range 6-51 mg/kg) 1

Children Aged 2 to <4 Years

  • Starting dose: 8-10 mg/kg/day (not exceeding 600 mg/day), divided twice daily 1
  • For patients <20 kg: Consider starting at 16-20 mg/kg/day 1
  • Titration: Achieve maximum maintenance over 2-4 weeks 1
  • Maximum: Should not exceed 60 mg/kg/day 1

Alternative Titration Strategies

While the FDA label provides the official dosing, clinical experience suggests slower titration may improve tolerability 2, 3, 4:

  • Start at 150 mg at night
  • Increase by 150 mg every 2 days until reaching 900-1200 mg/day 2
  • Alternative: Start at 300 mg daily, increase by 300 mg weekly 4

This slower approach balances efficacy with tolerability, particularly important given that oxcarbazepine demonstrates superior tolerability compared to carbamazepine (14% vs 26% discontinuation due to adverse events) and phenytoin (2% vs 14.5% discontinuation in children) 5.

Special Populations

Renal Impairment

  • Creatinine clearance <30 mL/min: Initiate at half the usual starting dose and increase slowly 1
  • Elimination half-life of MHD (active metabolite) is prolonged 2-fold in severe renal impairment 6

Hepatic Impairment

  • Mild to moderate: No dose adjustment needed 3, 6

Drug Interactions Requiring Dose Adjustment

  • Enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital): Reduce MHD levels by 30-40%; may require higher oxcarbazepine doses 1, 6
  • Concomitant phenytoin: At oxcarbazepine doses >1200 mg/day, phenytoin levels increase by 40%; phenytoin dose reduction may be necessary 6

Clinical Context

The evidence supporting these dosing recommendations comes from multiple Class I studies demonstrating oxcarbazepine's equivalence to carbamazepine, phenytoin, and valproate in efficacy (52-61% seizure-free rates), with superior tolerability 5. In children aged 5-18 years, oxcarbazepine showed 61% seizure freedom with only 2% discontinuation versus 14.5% with phenytoin 5.

Critical caveat: Monitor for hyponatremia (serum sodium <125 mmol/L), which develops in approximately 3% of patients during the first months of therapy 2. Baseline sodium measurement is unnecessary unless patients have renal disease, take medications that lower sodium (diuretics, NSAIDs, oral contraceptives), or develop symptoms of hyponatremia 2.

Important warning: Oxcarbazepine decreases ethinylestradiol and levonorgestrel levels, potentially causing oral contraceptive failure; additional contraceptive precautions are necessary 4, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.